Finance Watch: VC Investment Soars In Q1, Putting Biopharma On Track For A Record Year
Executive Summary
Pharma and biotech companies raised $4.6bn in the first quarter, exceeding the 2017 quarterly average by $1.4bn. But while the money invested soared, the number of companies funded sank. In public financings, MorphoSys commences US IPO and Mylan sells $1.5bn in notes.
You may also be interested in...
Ready To Make Bigger Biotech Investments, Vida Raises $600m For Second Fund
Scrip spoke with Fred Cohen, who co-founded Vida Ventures with former Kite Pharma CEO Arie Belldegrun, about the venture capital firm's investment focus after raising its second fund in two years.
Finance Watch: High Value Of Exits Keep Biopharma VC Deals At Near-Record Levels
Private Company Edition: IPOs and M&A are returning money to investors, who are putting that money into new investments. Also, the mega-push in VC mega-rounds continues, including $105m for Kronos, and RA Capital raises it first VC fund.
Asian Investors Bankroll €40m Promethera Biosciences Series D
Liver disease-focused Belgian cell therapy biotech Promethera Biosciences closes a €39.7m ($44.4m) Series D round co-led by new Japanese investors Itochu Corporation and Shinsei Capital Partners. Asian investors now own about 44% of company.